Elevance Health

Moat composition: 1) Intangible assets: Blue Cross/Blue Shield licenses and local Anthem Blue branding in 14 states provide recognition and preferred networks.

This is durable, though licensing rules and recent settlements slightly increase competitive exposure at the margin. 2) Switching costs: Highest for large employers and public programs where plan design, networks, and care management integration create inertia; lower for individuals on exchange products. 3) Cost advantages: Scale in underwriting, pharmacy services, and analytics plus large provider networks help rate competitiveness. 4) Efficient scale: Many markets (state Medicaid, select geographies) are rational with limited slots. 5) Network effects: Limited direct network effects, though value improves as provider partnerships deepen.

On durability, we adjust down for the Subscriber Settlement (eliminating the national best‑efforts rule and allowing a second Blue bid for certain national accounts) and the Provider Settlement requirements, which modestly raise competitive intensity. Overall, multiple moderate moats rather than a single dominant one.

Pricing power is present but constrained by regulation and competition. Elevance has historically passed trend in Commercial and secured rate actions in Government over time, but 2025 shows elevated medical trend in Medicare and ACA that is not immediately priced, pressuring margins.

Pharmacy cost inflation (notably GLP‑1 utilization) is an industry headwind, even as the firm deploys digital weight‑management programs and utilization controls. Net, Elevance exhibits steady, if regulated, price realization with limited latent pricing upside relative to monopolistic tollbooths.

Revenue is highly recurring and diversified across Commercial, Medicare, and Medicaid with scale pharmacy operations. 2025 revenue grew double‑digits, but earnings are more volatile because benefit expense ratio fluctuates with utilization and policy.

MA Star improvements lift medium‑term visibility, yet Medicaid redeterminations and IRA Part D redesign introduce noise. Compared with cyclical industries, predictability is good; compared with pure tollbooths, variability is higher.

Debt metrics are reasonable for a regulated payer: debt‑to‑capital around 42% at Q3 2025; liquidity includes $8.7B cash and robust investment portfolios at operating subsidiaries.

TTM operating cash flow is temporarily reduced by the BCBSA Provider Settlement payment and working capital timing, with TTM FCF we compute near $3.77B through Q3 2025. Capital needs are modest; RBC levels exceed requirements. We view bankruptcy risk as remote, but we mark down for litigation outflows and cost trend uncertainty.

Management prioritizes reinvestment in services (CarelonRx, Carelon Services), tuck‑ins (CareBridge), and primary care enablement (Mosaic Health) to support the benefits/services flywheel, while returning capital via buybacks and a growing dividend. 2024 cash dividends rose to $1.71 per quarter in 2025; share repurchases totaled about $2.1B YTD through Q3 2025 with shares outstanding falling from 227.5M at year‑end 2024 to roughly 222.0M by Q3 2025. Stock‑based compensation is modest relative to cash returns.

Track record on large M&A is prudent; current deals are programmatic and strategically aligned.

CEO Gail Boudreaux brings deep managed care experience and has steered Elevance from a pure insurer toward an integrated health company. The CFO transition to Mark Kaye added disciplined financial stewardship.

Leadership has communicated a long‑term algorithm of at least high‑single‑ to low‑double‑digit adjusted EPS growth and continues to reinvest into care models and technology while balancing capital returns. Execution through 2025’s cost pressure appears measured, with guidance resets and reaffirmations consistent with controllables.